Literature DB >> 29030765

Cerebrospinal fluid analysis and the determination of oligoclonal bands.

Matteo Gastaldi1, Elisabetta Zardini1, Rosaria Leante2, Maddalena Ruggieri2, Gianna Costa3, Eleonora Cocco3, Giovanna De Luca4, Ivana Cataldo4, Tiziana Biagioli5, Clara Ballerini6, Massimiliano Castellazzi7, Enrico Fainardi6, Paola Pettini8, Mauro Zaffaroni8, Debora Giunti9, Elisabetta Capello9, Gaetano Bernardi10, Emilio Ciusani10, Claudia Giannotta11, Eduardo Nobile-Orazio11, Elena Bazzigaluppi12, Gabriella Passerini12, Roberta Bedin13, Patrizia Sola13, Rinaldo Brivio14, Guido Cavaletti15, Arianna Sala16, Antonio Bertolotto16, Gaetano Desina17, Maurizio A Leone17, Sara Mariotto18, Sergio Ferrari18, Andreina Paternoster19, Davide Giavarina19, Francesco Lolli6, Diego Franciotta20.   

Abstract

This document presents the guidelines for the cerebrospinal fluid (CSF) analysis and the determination of oligoclonal bands (OCBs) as pivotal tests in neuroinflammatory pathologies of the central nervous system. The guidelines have been developed following a consensus process built on questionnaire-based surveys, internet contacts, and discussions at workshops of the sponsoring Italian Association of Neuroimmunology (AINI) congresses. Essential clinical information on the pathologies in which the CSF analysis is indicated, and, particularly, on those characterized by the presence of OCBs in the intrathecal compartment, indications and limits of CSF analysis and OCB determination, instructions for result interpretation, and agreed laboratory protocols (Appendix) are reported for the communicative community of neurologists and clinical pathologists.

Entities:  

Keywords:  Intrathecal IgG synthesis; Isoelectric focusing; Laboratory diagnostics; Multiple sclerosis; Neuroimmunology

Mesh:

Substances:

Year:  2017        PMID: 29030765     DOI: 10.1007/s10072-017-3034-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  46 in total

1.  Discontinuous distribution of IgG oligoclonal bands in cerebrospinal fluid from multiple sclerosis patients.

Authors:  G Martino; L M Grimaldi; L Moiola; M Filippi; V Martinelli; G Comi; N Canal
Journal:  J Neuroimmunol       Date:  1990-12       Impact factor: 3.478

2.  The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice.

Authors:  Antonio Bertolotto; Maria Malentacchi; Marco Capobianco; Alessia di Sapio; Simona Malucchi; Yana Motuzova; Annalisa Pulizzi; Paola Berchialla; Francesca Sperli
Journal:  Cephalalgia       Date:  2015-04-23       Impact factor: 6.292

3.  Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.

Authors:  Luisa M Villar; Lucienne Costa-Frossard; Thomas Masterman; Oscar Fernandez; Xavier Montalban; Bonaventura Casanova; Guillermo Izquierdo; Francisco Coret; Hayrettin Tumani; Albert Saiz; Rafael Arroyo; Katharina Fink; Laura Leyva; Carmen Espejo; María Simó-Castelló; María I García-Sánchez; Florian Lauda; Sara Llufriú; Roberto Álvarez-Lafuente; Javier Olascoaga; Alvaro Prada; Agustín Oterino; Clara de Andrés; Mar Tintoré; Lluis Ramió-Torrentà; Eulalia Rodríguez-Martín; Carmen Picón; Manuel Comabella; Ester Quintana; Eduardo Agüera; Santiago Díaz; Ricardo Fernandez-Bolaños; Juan A García-Merino; Lamberto Landete; Manuel Menéndez-González; Laura Navarro; Domingo Pérez; Fernando Sánchez-López; Pedro J Serrano-Castro; Alberto Tuñón; Mercedes Espiño; Alfonso Muriel; Amit Bar-Or; José C Álvarez-Cermeño
Journal:  Ann Neurol       Date:  2015-01-30       Impact factor: 10.422

4.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

5.  External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients.

Authors:  H Reiber
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

Review 6.  An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.

Authors:  Matteo Gastaldi; Elisabetta Zardini; Diego Franciotta
Journal:  Expert Rev Mol Diagn       Date:  2016-12-02       Impact factor: 5.225

7.  Polymerase chain reaction analysis and oligoclonal antibody in the cerebrospinal fluid from 34 patients with varicella-zoster virus infection of the nervous system.

Authors:  S M Gregoire; V van Pesch; S Goffette; A Peeters; C J M Sindic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04-25       Impact factor: 10.154

8.  Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment.

Authors:  N García-Barragán; L M Villar; M Espiño; M C Sádaba; P González-Porqué; J C Alvarez-Cermeño
Journal:  Eur J Neurol       Date:  2009-03       Impact factor: 6.089

Review 9.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.

Authors:  M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

10.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

View more
  6 in total

1.  Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis.

Authors:  Juan A Gallego; Emily A Blanco; Sehba Husain-Krautter; E Madeline Fagen; Paula Moreno-Merino; Juan A Del Ojo-Jiménez; Anthony Ahmed; Thomas L Rothstein; Todd Lencz; Anil K Malhotra
Journal:  Schizophr Res       Date:  2018-07-17       Impact factor: 4.939

2.  Anti-N-methyl-D-aspartate receptor encephalitis: a prospective study focused on cerebrospinal fluid and clinical symptoms.

Authors:  Shouyi Wu; Huiqin Li; Yajun Lian; Yuan Chen; Yake Zheng; Chengze Wang; Qiaoman Zhang; Zhi Huang; Zhengrong Mao; Kai Pang
Journal:  Neurol Sci       Date:  2020-05-12       Impact factor: 3.307

3.  Extreme Diversity of IgGs Against Histones, DNA, and Myelin Basic Protein in the Cerebrospinal Fluid and Blood of Patients with Multiple Sclerosis.

Authors:  Irina A Kostrikina; Valentina N Buneva; Enrico Granieri; Georgy A Nevinsky
Journal:  Biomolecules       Date:  2020-04-18

4.  Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient.

Authors:  Massimiliano Castellazzi; Andrea Morotti; Carmine Tamborino; Francesca Alessi; Silvy Pilotto; Eleonora Baldi; Luisa M Caniatti; Alessandro Trentini; Ilaria Casetta; Enrico Granieri; Maura Pugliatti; Enrico Fainardi; Tiziana Bellini
Journal:  Fluids Barriers CNS       Date:  2020-02-05

5.  Sex-Related Differences in Cerebrospinal Fluid Plasma-Derived Proteins of Neurological Patients.

Authors:  Massimiliano Castellazzi; Caterina Ferri; Sarah Alfiero; Ilenia Lombardo; Michele Laudisi; Ginevra Tecilla; Michela Boni; Stefano Pizzicotti; Enrico Fainardi; Tiziana Bellini; Maura Pugliatti
Journal:  Diagnostics (Basel)       Date:  2021-05-16

6.  Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses.

Authors:  Saskia Räuber; Michael Heming; Jonathan Repple; Tillmann Ruland; Rebecca Kuelby; Andreas Schulte-Mecklenbeck; Catharina C Gross; Volker Arolt; Bernhard Baune; Tim Hahn; Udo Dannlowski; Sven G Meuth; Nico Melzer; Heinz Wiendl; Gerd Meyer Zu Hörste
Journal:  Mol Psychiatry       Date:  2021-08-06       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.